To include your compound in the COVID-19 Resource Center, submit it here.

Tuning into stereochemistry

Chiron Corp. has not been shy about striking deals related to its intellectual property for the development of therapeutics for hepatitis C virus (HCV). The company has licensed non-exclusive rights to at least seven pharma companies, a strategy

Read the full 387 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers